Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
plasma
Pharma
CSL cuts FY26 revenue projection by $600M, writes off $5B
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion and is taking a $5 billion asset impairment.
Kevin Dunleavy
May 11, 2026 11:30am
CSL firms up details on $1.5B US plasma-based medicines plant
Mar 10, 2026 10:30am
Beleaguered CSL announces surprise CEO retirement
Feb 10, 2026 10:45am
Takeda plasma-derived therapies team tackles Mount Fuji
Sep 19, 2025 3:22pm
Grifols deflects private equity firm's potential takeover offer
Nov 20, 2024 10:13am
Record plasma collections spark a revenue boost for CSL
Aug 16, 2023 11:32am
